Plant Name: Vernonanthura pinguis
Taxonomic Information:
Plant ID: NPO962
Plant Latin Name: Vernonanthura pinguis
Taxonomy Genus: Vernonanthura
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; | |
| ACHE; | |
| ADK; NOX4; HSD17B1; | |
| FLT3; CSNK2A1; | |
| CA2; CA4; CA12; CA7; | |
| ESR2; | |
| MMP12; | |
| HIF1A; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.080E-09 | 1.522E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.398E-09 | 1.522E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.018E-09 | 6.546E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.865E-08 | 8.416E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.944E-08 | 1.079E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 9.264E-08 | 1.552E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.322E-07 | 1.977E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.362E-07 | 1.977E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.208E-07 | 3.005E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 3.145E-07 | 3.886E-04 | ADORA2A, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 5.102E-07 | 5.555E-04 | ADORA2A, CA2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.454E-06 | 1.218E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.934E-06 | 1.504E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 2.759E-06 | 1.821E-03 | ADORA1, ADORA2A, ADORA3, CSNK2A1, CYP1B1, FLT3, HIF1A, MMP12, NOX4, THPO |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.375E-06 | 1.986E-03 | CA2, CA7 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.375E-06 | 1.986E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.746E-06 | 3.193E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0009967; positive regulation of signal transduction | 1.375E-05 | 6.112E-03 | ADORA1, ADORA2A, CSNK2A1, CYP1B1, FLT3, HIF1A, MMP12, NOX4, THPO |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 2.002E-05 | 8.072E-03 | ACHE, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, FLT3, HIF1A |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.431E-05 | 8.823E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.377E-09 | 9.286E-08 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.118E-09 | 9.286E-08 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.004E-07 | 3.675E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.614E-06 | 1.322E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.919E-05 | 6.510E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.376E-05 | 7.678E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.622E-04 | 2.060E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; ADORA2A; ADK; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; FLT3; ACHE; HIF1A; ADORA3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
